Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?

AIDS. 2024 Mar 15;38(4):603-605. doi: 10.1097/QAD.0000000000003816. Epub 2024 Feb 29.

Authors

Daniel Lee¹, Jacqueline Capeau²

Affiliations

¹ University of California, San Diego Health, Owen Clinic, Division of Infectious Diseases & Global Public Health, San Diego, California, USA.
² Inserm UMR_S938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Sorbonne Université, Paris, France.

PMID: 38416553
DOI: 10.1097/QAD.0000000000003816

No abstract available

Publication types

Editorial
Comment

MeSH terms

Glucagon-Like Peptide-1 Receptor Agonists*
Glucagon-Like Peptides / therapeutic use
HIV Infections* / complications
HIV Infections* / drug therapy
Humans
Weight Loss

Substances

semaglutide
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptides